NicVAX® (Nicotine Conjugate Vaccine) is an investigational vaccine designed as an aid to smoking cessation, as well as an aid to prevent relapses of a treated smoker leading to long-term abstinence.

NicVAX represents an extension of our conjugate vaccine technology that allows us to address a significant unmet medical need. We believe that broad commercialization of NicVAX requires large-scale sales and marketing programs focused on primary care physicians. As such we have secured an option and license agreement with GlaxoSmithKline (GSK), one of the leading global pharmaceutical companies. GSK has also depth of vaccine development and commercialization as well as smoking cessation expertise that should be an asset in our effort to successfully bring NicVAX to market.